Co-Creation Opportunity for Asia-Pacific Government & Payer Leaders
As COVID-19 has taught us, the quest for solutions to major public health challenges (infectious and non-communicable alike) starts with – and depends on – diagnostic technology. In line with the WHO Essential Diagnostics List (EDL) and Lancet Commission efforts, APACMed and its members have come together to produce an inaugural paper about the value delivered by diagnostic technologies in the Asia Pacific. And yet, despite accounting for 70%+ of clinical decision-making, diagnostic technologies receive <1% in resource allocation of total healthcare expenditures. The purpose of this paper, therefore, is to provide a platform for public-private dialogue on improving the value recognition of diagnostic technologies by governments and payers in the region, using live case studies to demonstrate the potential for a shared journey toward sustainable population health.